Brain Injury Research

KEY FINDING: Chronic treatment with either fluoxetine or sertraline, two different SSRIs, did not affect the recovery of serotonin axon length in the somatosensory cortex, visual cortex, or hippocampus.

KEY FINDING: The way in which function is lost after injury is the consequence of a complex array of mechanisms that continue in the chronic phase post-injury to prevent effective neural repair.

KEY FINDING: The crude 1- and 5-year mortality rates for DoC patients in Salzburg North were 25.9% and 55.1%, respectively.

KEY FINDING: During the first lockdown in the winter of 2020/2021, there was a notably lower incidence of moderate and severe TBIs compared to the corresponding period in 2019/2020 (p = 0.016).

KEY FINDING: Spontaneous activities, including travelled distance and rearing up counts, were significantly decreased in mice receiving CCI at 1 and 2 days after injury, which was strongly correlated with neurological score and tissue damage.

KEY FINDING: Brain injury or tacrolimus alone, or their combination, alleviated muscle atrophy and nerve fiber impairment while improving sciatic nerve function.

KEY FINDING: Consensus established 18 interventions as fundamental for sTBI care and ten treatments not to be used except in special circumstances.

KEY FINDING: PKCγ is activated in the corticospinal tract (CST) on the uninjured side of the brain after TBI, suggesting it plays a role in the brain's response to injury.

KEY FINDING: Established three distinct treatment protocols for managing sTBI patients with combined ICP and brain oxygen monitoring: one for ICP elevation with normal brain oxygenation, one for brain hypoxia with normal ICP, and one for both conditions present.

KEY FINDING: mTBI induced significant decreases in the diameters and RBC velocities of arterioles and capillaries from 0.5 to 6 hours post-injury, with partial recovery by 1 day.